NUTM2E: A Potential Drug Target and Biomarker for Diseases (G283008)

Target Name: NUTM2E

NCBI ID: G283008

NUTM2E

Other Name(s): FAM22E | Family with sequence similarity 22, member E | NUT family member 2E | family with sequence similarity 22, member E

NUTM2E: A Potential Drug Target and Biomarker for Diseases

NUTM2E (FAM22E), a protein located in the nuclear envelope of cells, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function make it an attractive target for drug development due to its ability to modulate the expression of genes involved in cell growth, differentiation, and survival.

The nuclear envelope, a double layer of phospholipids and proteins that surrounds the nucleus of a cell, plays a crucial role in maintaining the integrity of the cell and regulating the flow of molecules into and out of the nucleus. NUTM2E, a protein that belongs to the FAM22 family, is a key component of the nuclear envelope and has been shown to participate in various cellular processes, including cell signaling, DNA replication, and repair.

One of the key functions of NUTM2E is its role in regulating the expression of genes involved in cell growth and differentiation. NUTM2E has been shown to interact with various transcription factors, including nuclear factor E2 (NFE2), which plays a critical role in regulating the expression of genes involved in cell growth, differentiation, and survival. NUTM2E has been shown to physically interact with NFE2 and enhance its transcriptional activity. This interaction between NUTM2E and NFE2 suggests a potential role for NUTM2E as a drug target involved in the regulation of cellular processes that are associated with various diseases.

In addition to its role in regulating gene expression, NUTM2E has also been shown to play a key role in the regulation of cellular signaling pathways. NUTM2E has been shown to interact with various signaling molecules, including the protein tyrosine kinase (TK) and the transcription factor PDGF-2 (PDGF2). These interactions suggest a potential role for NUTM2E in the regulation of cellular signaling pathways that are involved in various diseases, including cancer and neurodegenerative diseases.

The potential drug targets associated with NUTM2E include various proteins that are involved in cell signaling, including TK, PDGF2, and NF-kappa-B signaling pathway components. These proteins have been shown to interact with NUTM2E and are involved in the regulation of cellular processes that are associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Therefore, NUTM2E may be a promising biomarker and drug target for these diseases.

In conclusion, NUTM2E is a protein that has been identified as a potential drug target and biomarker for various diseases due to its unique structure and function. Its ability to modulate the expression of genes involved in cell growth, differentiation, and survival, as well as its role in regulating cellular signaling pathways, make NUTM2E an attractive target for drug development. Further research is needed to fully understand the role of NUTM2E in the regulation of cellular processes and its potential as a drug target and biomarker for various diseases.

Protein Name: NUT Family Member 2E

The "NUTM2E Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NUTM2E comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets